Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: A detailed systematic analysis using published data

Histopathology

Volumn 48, Issue 3, 2006, Pages 223-232

  King, J E ^a,c   Thatcher, N ^b   Pickering, C A C ^a   Hasleton, P S ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Biopsy; Immunohistochemistry; Mesothelioma; Pleural diseases; Pleural neoplasm

Indexed keywords

BER EP4 ANTIBODY; CALRETININ; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD15 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN ANTIBODY; MOC 31 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY HBME 1; NERVE CELL ADHESION MOLECULE; PROTEIN ANTIBODY; THROMBOMODULIN; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WILM TUMOR PRODUCT 1; B72.3 ANTIBODY; CADHERIN; CALBINDIN; CANCER ANTIBODY; LEU M1 ANTIGEN, HUMAN; LEU-M1 ANTIGEN, HUMAN; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; BLOOD GROUP LEWIS SYSTEM; CANCER DIAGNOSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EPITHELIOID CELL; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STAINING; SYSTEMATIC REVIEW; UNCERTAINTY; ADENOCARCINOMA; CHEMISTRY; LUNG TUMOR; METHODOLOGY; PLEURA TUMOR;

ZIZIPHUS MAURITIANA;

ADENOCARCINOMA; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CADHERINS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 33644972822     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02331.x     Document Type: Review

References (116)

1. McCaughey W Colby T Battifora H et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel ModPathol 1991 4 342 353
2. Gold P Freeman S. Specific carcinoembryonic antigens of the human digestive system JExpMed 1965 122 467 481
3. Wang N Huang S Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers Cancer 1979 44 937 943
4. Al-Saffar N Hasleton P. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions EurRespJ 1990 3 997 1001
5. Brockstedt U Gulyas M Dobra K Dejmek A Hjerpe A. Optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from carcinoma AmJClinPathol 2000 114 203 209
6. Brown R Clark G Tandon A Allred D. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma HumPathol 1993 24 347 354
7. Cagle P Brown R Lebovitz R. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens HumPathol 1994 25 443 448
8. Chenard-Neu M Bellocq J Maier A Batzenschlager A. Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects AnnPathol 1990 10 20 27
9. Collins C Ordóñez N Schaefer R et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma AmJPathol 1992 141 827 833
10. Corson J Pinkus G. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas AmJPathol 1982 108 80 87
11. Dejmek A Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis APMIS 1994 102 255 264
12. Dejmek A Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies Cancer 1994 73 464 469
13. Dewar A Valente M Ring N Corrin B. Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: an ultrastructural and cytochemical comparison JPathol 1987 152 309 316
14. Garcia-Prats M Ballestin C Sotelo T Lopez-Encuentra A Mayordomo J. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours Histopathology 1998 32 462 472
15. Ghosh A Gatter K Dunnill M Mason D. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies JClinPathol 1987 40 19 25
16. Gibbs A Harach R Wagner J Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma Thorax 1985 40 91 95
17. Grove A Paulsen S Gregersen M. The value of immunohistohemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma PatholResPract 1994 190 1044 1055
18. Holden J Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma AmJSurgPathol 1984 8 277 279
19. Lee I Radosevich J Chejfec G et al. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12 AmJPathol 1986 123 497 507
20. Loosli H Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura Histopathology 1984 8 793 803
21. Moch H Oberholzer M Dalquen P Wegmann W Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I. Immunohistochemical findings Virchows ArchA PatholAnat 1993 423 19 27
22. O'Hara C Corson J Pinkus G Stahel R. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies AmJPathol 1990 136 421 428
23. Ordóñez N. The immunohistochemical diagnosis of mesothelioma AmJSurgPathol 1989 13 276 291
24. Ordóñez N. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. A comparative study with other commonly used antibodies AmJSurgPathol 1997 21 1399 1408
25. Otis C Carter D Cole S Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases AmJSurgPathol 1987 11 445 456
26. Pfaltz M Odermatt B Christen B Ruttner J. Immunohistochemistry in the diagnosis of malignant mesothelioma Virchows ArchA PatholAnatHistopathol 1987 411 387 393
27. Riera J Astengo-Osuna C Longmate J Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval AmJSurgPathol 1997 21 1409 1419
28. Roberts F Harper C Downie I Burnett R. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies AmJClinPathol 2001 116 253 262
29. Said J Nash G Banks-Schlegel S et al. Keratin in human lung tumors. Patterns of localisation of different-molecular-weight keratin proteins AmJPathol 1983 113 27 32
30. Soosay G Griffiths M Papadaki L Happerfield L Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation JPathol 1991 163 299 305
31. Szpak C Johnston W Roggli V et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3) AmJPathol 1986 122 252 260
32. Tron V Wright J Churg A. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung ArchPatholLabMed 1987 111 291 293
33. Tuttle S Lucas J Bucci D Schlom J Primus J. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies JSurgOncol 1990 45 72 78
34. Kayser K Bohm G Blum S et al. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients JPathol 2001 193 175 180
35. Doglioni C Dei Tos A Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma AmJSurgPathol 1996 20 1037 1046
36. Leers M Aarts M Theunissen P. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma Histopathology 1998 32 209 216
37. Wirth P Legier J Wright G. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesohelioma from lung adenocarcinoma Cancer 1991 67 655 662
38. Whitaker D Sterrett G Shilkin K. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma Pathology 1982 14 255 258
39. Battifora H Kopinski M. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach Cancer 1985 55 1679 1685
40. Friemann J Otto H Muller K. Immunohistochemical studies for the differential diagnosis of primary and secondary pleural tumors [In German] VerhDtsch GesPathol 1986 70 311 316
41. Jasani B Edwards R Thomas N Gibbs A. The use of vimentin antibodies in the diagnosis of malignant mesothelioma Virchows ArchS PatholAnatHistopathol 1985 406 441 448
42. Kwee WS Veldhuizen RW Golding RP et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining Virchows ArchA PatholAnatHistol 1982 397 287 299
43. Kawai T Greenberg SD Titus JL. Lectin histochemistry of normal lung and pulmonary adenocarcinoma ModPathol 1988 1 485 492
44. Lucas J Tuttle S. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma JSurgOncol 1987 35 30 34
45. a, and anti-Tn antibodies HumPathol 1989 20 53 57
46. Wick M Loy T Mills S Legier J Manivel J. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases HumPathol 1990 21 759 766
47. Marshall RJ Herbert A Braye SG Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium JClinPathol 1984 37 1215 1221
48. Sheibani K Battifora H Burke J Rappaport H. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases AmJSurgPathol 1986 10 227 236
49. Chenard-Neu M-P Kabou A Mechine A et al. L'immunohistochimie dans le diagnostic différentiel entre mésothéliome et adenocarcinome AnnPathol 1998 18 460 465
50. Comin CE Novelli L Boddi V Paglierani M Dini S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma HumPathol 2001 32 529 536
51. Carella R Deleonardi G D'Errico A et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis AmJSurgPathol 2001 25 43 50
52. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma AmJSurgPathol 2003 27 1031 1051
53. Gumurdulu D Zeren EH Cagle PT et al. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages PatholOncolRes 2002 8 188 193
54. Latza U Niedobitek G Schwarting R Nekarda H Stein H. Ber-EP4: a new monoclonal antibody which distinguishes epithelia from mesothelia JClinPathol 1990 43 213 219
55. Gaffey MJ Mills SE Swanson PE et al. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas AmJSurgPathol 1992 16 593 599
56. Sheibani K Shin S Kezirian J Weiss L. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma vs adenocarcinoma AmJSurgPathol 1991 15 779 784
57. Warnock M Stoloff A Thor A. Differentiation of adenocarcinoma from mesothelioma: periodic acid-Schiff, monoclonal antibodies B72.3 and Leu-M1 AmJPathol 1988 133 30 38
58. Wick M. Immunophenotyping of malignant mesothelioma AmJSurgPathol 1997 21 1395 1398
59. Oates J Edwards C. HBME-1, MOC-31, WT-1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma Histopathology 2000 36 341 347
60. Ordóñez N. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma HumPathol 1998 29 166 169
61. Sosolik RC McGaughy VR De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel ModPathol 1997 10 716 719
62. Han A Peralta-Soler A Knudsen K et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues HumPathol 1997 28 641 645
63. Ordóñez N. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma AmJSurgPathol 2000 24 598 606
64. Peralta-Soler A Knudsen K Jaurand M. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas HumPathol 1995 26 1363 1369
65. Thirkettle I Harvey P Hasleton P Ball R Warn R. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas Histopathology 2000 36 522 528
66. Abutaily AS Addis BJ Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies JClinPathol 2002 55 662 668
67. Khoor A Whitsett J Stahlman M Olson S Cagle P. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from mesothelioma HumPathol 1999 30 695 700
68. Di Loreto C Puglisi F Di Lauro V Damante G Beltrami C. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung Cancer Lett 1998 124 73 78
69. y in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma AmJPathol 1989 135 931 937
70. Clover J Oates J Edwards C. Anticytokeratin 5/6: a positive marker for epithelioid mesothelioma Histopathology 1997 31 140 143
71. Ordóñez N. Value of cytokeratin 5/6 in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma AmJSurgPathol 1998 22 1215 1221
72. Cury PM Butcher DN Fisher C Corrin B Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura ModPathol 2000 13 107 112
73. Chu PG Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases ModPathol 2002 15 6 10
74. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma AmJSurgPathol 1985 9 360 365
75. Mullink H Henzen-Logmans S Alons-van Kordelaar J Tadema T Meijer C. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma Virchows ArchB Cell PatholInclMolPathol 1986 52 55 65
76. Upton MP Hirohashi S Tome Y et al. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung AmJSurgPathol 1986 10 560 567
77. Battifora H McCaughey W. Tumors of the serosal membranes, Fascicle 15, 3rd Series. Washington DC Armed Forces Institute of Pathology 1994
78. Vortmeyer A Preuss J Padberg B Kastendieck H Schröder S. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas - a clinicomorphological study of 158 cases Anticancer Res 1991 11 889 894
79. Gotzos V Vogt P Celio M. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type PatholResPract 1996 192 137 147
80. Ordóñez N. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma ModPathol 1998 11 929 933
81. Foster MR Johnson JE Olson SJ Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas ArchPatholLabMed 2001 125 1316 1320
82. Miettinen M Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura AmJSurgPathol 2003 27 150 158
83. Stahel R O'Hara C Waibel R Martin A. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma IntJCancer 1988 41 218 223
84. Sheibani K Esteban J Bailey A Battifora H Weiss L. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma HumPathol 1992 23 107 116
85. Donna A Betta P-G Chiodera P et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature of so-called antimesothelioma antibodies HumPathol 1997 28 929 937
86. Attanoos RL Goddard H Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma Histopathology 1996 29 209 215
87. Kennedy A King G Kerr K. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura JClinPathol 1997 50 859 862
88. Dahlstrom J Maxwell L Brodie N Zardawi I Jain S. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas Pathology 2001 33 287 291
89. Esmon NL Owen WG Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C JBiolChem 1982 257 859 864
90. Yonezawa S Maruyama I Sakae K et al. Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin AmJClinPathol 1987 88 405 411
91. Fink L Collins C Schaefer R. Thrombomodulin expression can be used to differentiate between mesotheliomas and adenocarcinomas LabInvest 1992 66 113A
92. Amin K Litzky L Smythe W et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma AmJPathol 1995 146 344 356
93. Kumar-Singh S Segers K Rodeck U et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis JPathol 1997 181 67 74
94. Miettinen M Limon J Niezabitowski A Lasota J. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma AmJSurgPathol 2001 25 610 617
95. Hecht JL Lee BH Pinkus JL Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma Cancer 2002 96 105 109
96. Folpe A Gown A. Immunohistochemistry for analysis of soft tissue tumors. In Weiss S Goldblum J eds Soft tissue tumors 4th edn St Louis Mosby 2001 199 245
97. Sheibani K Battifora H Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen AmJPathol 1986 123 212 219
98. Attanoos R Webb R Gibbs A. CD 44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma Histopathology 1997 30 260 263
99. Filie AC Abati A Fetsch P Azumi N. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: disappointing results in cytology material DiagnCytopathol 1998 18 473 474
100. Afify A Stern R Jobes G Bailey J Werness B. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias ApplImmunohistochem 1998 6 11 15
101. Kortsik CS Werner P Freudenberg N et al. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3 - a new tumor marker Lung 1995 173 79 87
102. Edwards C Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed paraffin embedded material JClinPathol 1995 48 626 630
103. Delahaye M Hoogsteden HC Van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma JPathol 1991 165 137 143
104. Donna A Betta PG Bellingeri D Marchesini A. New marker for mesothelioma: an immunoperoxidase study JClinPathol 1986 39 961 968
105. Peto J Hodgson J Matthews F Jones J. Continuing increase in mesothelioma mortality in Britain Lancet 1995 345 535 539
106. Sahn S. Malignancy metastatic to the pleura Clinics Chest Med 1998 19 351 361
107. Travis W Colby T Corrin B Shimosato Y Brambilla E. WHO international histological classification of tumours: histological typing of lung and pleural tumours 3rd edn Springer Verlag 1999
108. King JE Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma Histopathology 2001 38 471 476
109. Van Gelder T Hoogsteden H Vandenbroucke J Van der Kwast T Planteydt H. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma Virchows Arch(PatholAnat) 1991 418 315 317
110. Hasleton P. Pleural disease. In Hasleton P ed. Spencer's pathology of the lung 5th edn New York McGraw-Hill 1996 1131 1210
111. Henderson D Shilkin K Whitaker D et al. The pathology of malignant mesothelioma, including immunohistology and ultrastructure. In Henderson D Shilkin K Langlois S et al., eds Malignant mesothelioma New York Hemisphere Publishing Corporation 1992
112. Henderson D Shilkin K Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ AmJClinPathol 1998 110 397 404
113. Andrion A Magnani C Betta P et al. Malignant mesothelioma of the pleura: interobserver variability JClinPathol 1995 48 856 860
114. Legier J Maddox J. Immunohistochemical diagnosis of mesothelioma. In Jaurand M Bignon J eds The mesothelial cell and mesothelioma New York Marcel Dekker, Inc. 1994 103 119
115. Skov B Brændstrup O Hirsch F et al. Are pathologists biased by clinical information?: a blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma Lung Cancer 1994 11 365 372
116. Daly LE Bourke GJ. Interpretation and uses of medical statistics 5th edn Oxford Blackwell Scienceq3 2000 412 5